Insight journal

Big pharma partnering trends by deal type

Posted on 05 March 2013

Tags: , , , ,

Big pharma, or top pharmaceutical companies, sign a large number of partnering deals every year in order to progress their business interests.

This article forms part of a series looking at recent big pharma partnering and M&A activity in the pharmaceutical, biotech and life science industries, with abstracts from the report  Partnering Deals and Alliances with Bigpharma, providing comprehensive and in-depth insight into the deal making interests and activity of the leading fifty big pharma companies.

The top 50 pharmaceutical companies, often referred to as big pharma, include the likes of Pfizer, Sanofi, GlaxoSmithKline and make up a large part of the pharmaceutical, biotech and life sciences industry’s revenue generation as well as research and development (R&D) effort.

A full list of the top pharmaceutical companies can be viewed here.

Big pharma, or top pharmaceutical companies, sign a large number of partnering deals every year in order to progress their business interests.

Collaborative R&D and licensing partnering deals allow big pharma companies to supplement their internal R&D and product pipeline with product and technology assets developed external to the company. Over 1,000 collaborative R&D and over 2,500 licensing deals were announced by big pharma companies in the last eight years. In addition, over 1,000 development deals and over 750 research deals were announced.

These R&D, licensing and technology access deals were supplemented by numerous deals that support the commercialization of assets by big pharma companies. These deals types include distribution and marketing deals.

Another type of deal is the co-promotion deals, where the two companies agree to co-promote the product to the market, with each party focussing on a slightly different area, for example country or target end user.

Current Partnering has published a special report on the topic of co-promotion – see: Co-promotion and Co-marketing Partnering Terms and Agreements.

Another area of significant activity is manufacturing and supply deals, where a third party makes and supplies product to the company for marketing and sale.

The following figure provides an overview of big pharma partnering by deal type, showing where the top pharmaceutical companies focus their partnering efforts.

Figure: Big pharma partnering by deal type 2005-2013

Big pharma partnering by deal type

Source: CurrentAgreements, February 2013

For details of each individual top pharma partnering activity by deal type, go to the big pharma partnering report series.

This article is based on the findings of the new report from Current Partnering titled Partnering Deals and Alliances with Bigpharma, providing comprehensive and in-depth insight into the deal making interests and activity of the leading fifty big pharma companies.

Steve Poile

Next > Big pharma partnering deal trends by stage of development

Previous > Big pharma mega partnering: fewer $1 billion plus deals

 

Related

Read: more on big pharma deals in pharma, biotech, life science partnering deal news, insights and glossary

Report: Partnering Deals and Alliances with Big Pharma

Reports: Big pharma company partnering report series

Report: Co-promotion and Co-marketing Partnering Terms and Agreements

Report: Distribution Partnering Terms and Agreements

Report: Manufacturing and Supply Partnering Terms and Agreements

View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value

View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making

View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter – reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Follow us on: LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter

Print Friendly

2 Responses to “Big pharma partnering trends by deal type”


Trackbacks/Pingbacks

  1. [...] . his article forms part of a series looking at recent big pharma partnering and M&A activity in the pharmaceutical, biotech and life science industries, with abstracts from the report Partnering Deals and Alliances with Bigpharma, providing comprehensive and in-depth insight into the deal making interests and activity of the leading fifty big pharma companies.Big pharma companies sign a large number of partnering deals every year with collaborative R&D and licensing being most popular deal type.  [...]

  2. [...] . his article forms part of a series looking at recent big pharma partnering and M&A activity in the pharmaceutical, biotech and life science industries, with abstracts from the report Partnering Deals and Alliances with Bigpharma, providing comprehensive and in-depth insight into the deal making interests and activity of the leading fifty big pharma companies.Big pharma companies sign a large number of partnering deals every year with collaborative R&D and licensing being most popular deal type.  [...]

Leave a Reply

 
bannerpng
ams-300x150jpg
biovision-300-x-150gif
RSS Feed Linked In Twitter

Latest Tweets

cp300x1502gif
biotechnology-2014header300x150pxjpg
emt14banner300x150jpg